Dublin, May 08, 2018 -- The "Exosomes & Liquid Biopsies Europe 2018" conference has been added to ResearchAndMarkets.com's offering.
The Exosomes and Liquid Biopsies Europe 2018 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby circulating biomarkers of various classes are being evaluated for their potential to be developed into minimally-invasive diagnostics and liquid biopsies for cancer as well as other disease classes.
This Exosomes and Liquid Biopsies 2018 Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), protein-based circulating biomarkers, and exosomes/extracellular vesicles (EVs). There is much interest in the potential of ctDNA and EVs for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this conference bring together the most up-to-date information and current state-of-the-field.
The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for early patient monitoring.
Another component of this conference is the exploration of the science behind Exosomes and Extracellular Vesicles - Diagnostic and Therapeutic Potential.
The conference is being held in Rotterdam, The Netherlands-an excellent venue for networking with connections across The Netherlands, Europe and Worldwide. The conference includes an exhibition bringing together companies from around the world focused on developing technologies, tools, products and services serving the liquid biopsy field.
The Conference Chairman and Chief Scientific Advisor is Professor Dominique de Kleijn, Professor, University Medical Center Utrecht, The Netherlands.
Agenda:
- Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
- Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
- Emerging Technologies and Emerging Companies Showcase
- Exosomes and Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
- Exosomes as Delivery Vehicles and Therapeutic Applications of Exosomes
- Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNAs and Circulating microRNAs/Long Non-Coding RNAs
- Extracellular Vesicles (EV) in Cancer, Cardiovascular Disease, Neurological Diseases and Beyond
- Grants and Awards across the EU for Exosomes and Liquid Biopsy Research
- Regulatory Landscape for Liquid Biopsies (EU, US and Asia/Pacific)
For more information about this conference visit https://www.researchandmarkets.com/research/bscdcc/exosomes_and?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics


Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
Nvidia AI Server Prices Set to Rise as Memory Costs Surge
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks
REPAY Stock Rises After Visa Platform Connect Collaboration
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
SK Hynix Shares Surge on Record $28.6 Billion Buyback
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
Barclays Downgrades Renault as Cost Savings Challenges Grow 



